[Effect on the central nervous system and circulatory system of new derivatives of perhydroazepine, perhydro-1,5-oxazocine, morpholine and piperazine containing a pharmacophoric 3-(isopropylamino)-propan-2-ol group].
D000818:Animals; D000959:Antihypertensive Agents; D001381:Azepines / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects*; D005260:Female; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009025:Morpholines / Q000494:pharmacology*; D009043:Motor Activity / Q000187:drug effects*; D010079:Oxazocines / Q000494:pharmacology*; D000077489:Piperazine; D010879:Piperazines / Q000494:pharmacology*; D011412:Propanolamines / Q000494:pharmacology; D051381:Rats; D014149:Tranquilizing Agents
D000959:Antihypertensive Agents; D001381:Azepines; D009025:Morpholines; D010079:Oxazocines; D010879:Piperazines; D011412:Propanolamines; D014149:Tranquilizing Agents; C048619:perhydro-1,5-oxazocine; D000077489:Piperazine; C037574:morpholine; C048618:hexahydroazepine
Badania wpływu na ośrodkowy układ nerwowy i układ krazenia nowych pochodnych perhydroazepiny, perhydro-1,5-oksazocyny, morfoliny i piperazyny zawierajacych farmakoforowa reszte 3-(izopropyloamino)-propan-2-olowa.